Also found in: Dictionary, Wikipedia.
Related to tapentadol: Tramadol


(ta-pen-ta-dol) ,


(trade name),

Nucynta ER

(trade name)


Therapeutic: analgesics
Pharmacologic: opioid agonists
Pregnancy Category: C


Management of moderate to severe pain; extended release product should be used for patients requiring around-the-clock management of chronic pain.Diabetic pain associated with diabetic peripheral neuropathy in patients requiring around-the-clock opioid analgesia for an extended time


Acts as μ-opioid receptor agonist.
Also inhibits the reuptake of norepinephrine.

Therapeutic effects

Decrease in pain severity.


Absorption: 32% absorbed following oral administration.
Distribution: Widely distributed.
Metabolism and Excretion: Undergoes extensive first-pass hepatic metabolism (97%); metabolites have no analgesic activity; metabolized drug is 99% renally excreted.
Half-life: 4 hr.

Time/action profile (analgesic effect)

POunknown1 hr4–6 hr


Contraindicated in: HypersensitivitySignificant respiratory depression in unmonitored settings or where resuscitative equipment is not readily available;Paralytic ileus;Severe hepatic or renal impairment;Concurrent MAO inhibitors or use of MAO inhibitors in the preceding 2 wk;Acute or severe bronchial asthma;Acute, mild, intermittent, or postoperative pain (extended-release only); Lactation: Lactation; Pediatric: Safety not established.
Use Cautiously in: Conditions associated with hypoxia, hypercapnea, or ↓ respiratory reserve including asthma, chronic obstructive pulmonary disease, cor pulmonale, extreme obesity, sleep apnea syndrome, myxedema, kyphoscoliosis, CNS depression, use of other CNS depressants or coma (↑ risk of further respiratory depression); use smallest effective dose;History of substance abuse or addiction disorder;Seizure disorders;Moderate hepatic impairment Geriatric: Elderly or debilitated patients (↑ risk of respiratory depression); consider age-related ↓ in hepatic, renal, and cardiovascular function, concurrent disease states and drug therapy (initial dose should be ↓); Obstetric: Use only if potential benefit justifies potential risk to the fetus.

Adverse Reactions/Side Effects

Central nervous system

  • seizures (life-threatening)
  • dizziness
  • headache
  • somnolence


  • respiratory depression (life-threatening)


  • hypotension


  • diarrhea
  • nausea
  • vomiting


  • angioedema (life-threatening)


Drug-Drug interaction

Concurrent MAO inhibitors or use of MAO inhibitors in the preceding 2 wk can result in potentially life-threatening adverse cardiovascular reactions due to additive effects on norepinephrine levels.Concurrent use of other CNS depressants including sedative/hypnotics, alcohol, antihistamines, antidepressants, phenothiazines, and other opioids ↑ risk of further CNS depression; consider dose ↓ of one or both agents.↑ risk of serotonin syndrome with SNRIs, SSRIs, triptans, tricyclic antidepressants, and MAO inihibitors.


When switching from immediate-release to extended-release product, the same total daily dose can be used.
Oral (Adults) Immediate-release or oral solution—50 mg, 75 mg, or 100 mg initially, then every 4–6 hr as needed and tolerated. If pain control is not achieved within first hour of first dose, additional dose may be given. Doses should not exceed 700 mg on the first day or 600 mg/day thereafter; Extended-release—50 twice daily; titrate dose up to 100–250 mg twice daily (not to exceed dose of 500 mg/day).

Hepatic Impairment

Oral (Adults) Moderate hepatic impairment—Immediate release or oral solution: 50 mg every 8 hr initially, then titrate to maintain analgesia without intolerable side effects; Extended-release: 50 mg once daily; may titrate up to maximum dose of 100 mg once daily, if needed.


Immediate-release tablets: 50 mg, 75 mg, 100 mg
Extended-release tablets: 50 mg, 100 mg, 150 mg, 200 mg, 250 mg
Oral solution: 20 mg/mL

Nursing implications

Nursing assessment

  • Assess type, location, and intensity of pain before and 1 hr (peak) after administration.
  • Assess BP and respiratory rate before and periodically during administration. Monitor for respiratory depression especially during initial dosing and with patients at increased risk.
  • Assess bowel function routinely. Prevention of constipation should be instituted with increased intake of fluids and bulk and with laxatives to minimize constipating effects. Administer stimulant laxatives routinely if opioid use exceeds 2–3 days, unless contraindicated.
  • Prolonged use may lead to physical and psychological dependence and tolerance, although these may be milder than with opioids. This should not prevent patient from receiving adequate analgesia. Most patients who receive tapentadol for pain do not develop psychological dependence.
  • Monitor patient for seizures. May occur within recommended dose range. Risk is increased in patients with a history of seizures and in patients taking antidepressants (SSRIs, SNRIs, tricyclics) or other drugs that decrease the seizure threshold.
  • Monitor for serotonin syndrome (mental-status changes [agitation, hallucinations, coma]), autonomic instability [tachycardia, labile BP, hyperthermia], neuromuscular aberrations [hyperreflexia, incoordination] and/or gastrointestinal symptoms [nausea, vomiting, diarrhea] in patients taking SSRIs, SNRIs, triptans, tricyclic antidepressants, or MAO inhibitors concurrently with tapentadol.
  • Overdose may cause respiratory depression. Naloxone (Narcan) may reverse some, but not all, of the symptoms of overdose. Treatment should be symptomatic and supportive. Maintain adequate respiratory exchange.

Potential Nursing Diagnoses

Acute pain (Indications)


  • Initial dose of 50 mg, 75 mg, or 100 mg is individualized based on pain severity, previous experience with similar drugs, and ability to monitor patient. Second dose may be administered as soon as 1 hr after first dose if adequate pain relief is not obtained with first dose.
  • Oral: Tapentadol may be administered without regard to meals.
    • Swallow extended-release tablets whole; do not crush, break or chew.
    • Use calibrated syringe to administer correct dose of oral solution.

Patient/Family Teaching

  • Instruct patient on how and when to ask for and take pain medication and to take tapentadol as directed; do not adjust dose without consulting health care professional. Report breakthrough pain and adverse reactions to health care professional. Do not take tapentadol if pain is mild or can be controlled with other pain medications such as NSAIDs or acetaminophen. Do not stop abruptly; may cause withdrawal symptoms (anxiety, sweating, insomina, rigors, pain, nausea, tremors, diarrhea, upper respiratory symptoms, hallucinations). Decrease dose gradually. Advise patient to read the Medication Guide prior to taking tapentadol and with each Rx refill, in case of new information.
  • Advise patient that tapentadol is a drug with known abuse potential. Protect it from theft, and never give to anyone other than the individual for whom it was prescribed; may be dangerous.
  • May cause dizziness and drowsiness. Caution patient to avoid driving or other activities requiring alertness until response to medication is known.
  • Inform patient that tapentadol may cause seizures. Stop taking tapentadol and notify health care professional immediately if seizures occur.
  • Advise patient to change positions slowly to minimize orthostatic hypotension.
  • Caution patient to avoid concurrent use of alcohol or other CNS depressants with this medication.
  • Instruct patient to notify health care professional of all Rx or OTC medications, vitamins, or herbal products being taken and consult health care professional before taking any new medications.
  • Advise patient to notify health care professional if signs of serotonin syndrome occur.
  • Encourage patient to turn, cough, and breathe deeply every 2 hr to prevent atelectasis.
  • Advise female patients to notify health care professional if pregnancy is planned or suspected, or if breast feeding.

Evaluation/Desired Outcomes

  • Decrease in severity of pain without a significant alteration in level of consciousness or respiratory status.
Drug Guide, © 2015 Farlex and Partners
References in periodicals archive ?
M2 PHARMA-September 1, 2010-PriCara says Clinical Drug Investigation publishes Phase III data for tapentadol ER in chronic osteoarthritis knee pain(C)2010 M2 COMMUNICATIONS
Tapentadol ER is a novel investigational, centrally acting oral analgesic that binds to mu-opioid receptors and inhibits norepinephrine re-uptake.
Opioids are another class of pain relief medication for canine arthritis treatment, which includes Tramadol, Tapentadol, and buprenorphine, among others.
While at Grunenthal GmbH, she led the clinical team during the EU and US regulatory submission and approval of tapentadol and most recently was head of its EU Innovative Medicines Unit hub in Leiden, Netherlands.
Alternatively, a compliant patient prescribed a synthetic opioid like fentanyl or tapentadol may face undue scrutiny because these drugs may not react with certain POC opiate assays.
If you are currently taking any of co-codamol, codeine, dihydrocodeine, tramadol, tapentadol, fentanyl, methadone, oxycodone, morphine or buprenorphine, you are taking an opioid painkiller, so read on The number of opioid prescriptions is increasing year on year.
In everyday practice, depending on the type of pain (receptor: somatic and visceral or neuropathic), the clinical condition of the patient, the coexisting diseases, and capacities of organs crucial for drug metabolism and excretion (liver and kidneys), different opioids are used, including morphine, oxycodone, hydromorphone, fentanyl, buprenorphine, tapentadol, methadone, tramadol, codeine; the last two are being classified as the so-called "weak" opioids.
At the moment, this is possible by associating drugs with a different action, such as an analgesic and an antidepressant or gabapentinoid, or by using a single, dual-acting analgesic, such as tapentadol, which presents opioid action, mediated by [mu] receptor agonism (MOR), synergic with a noradrenergic action due to the inhibition of noradrenalin reuptake (NRI, noradrenaline reuptake inhibitor) [10-14].
Surana, "Bio-fabrication and statistical optimization of polysorbate 80 coated chitosan nanoparticles of tapentadol hydrochloride for central antinociceptive effect: in vitro-in vivo studies," Artificial Cells, Nanomedicine, and Biotechnology, vol.